Quincy, Massachusetts Clinical Trials

A listing of Quincy, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 107 clinical trials
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

In this research study, is assessing the feasibility of using an MR-guided implantable microdevice to measure tumor response to chemotherapy and other clinically relevant drugs in participants that have prostate cancer and are scheduled for a radical prostatectomy. The name of the study intervention involved in this study is: Implantation …

carcinoma
prostatectomy
neutrophil count
Brigham and Women's Hospital
 (7.8 away) Contact site
  • 2 views
  • 19 Feb, 2024
  • 1 location
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)

alopecia
pembrolizumab
central nervous system disorder
aptt
cns disease
Dana Farber Cancer Institute
 (8.6 away) Contact site
  • 8 views
  • 19 Feb, 2024
  • 1 location
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

antiandrogen therapy
androgen suppression
androgens
gonadorelin
bilateral orchidectomy
Dana Farber Cancer Institute
 (8.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +5 other locations
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

thalidomide
immunotherapeutic agent
autologous hematopoietic stem cell transplant
multiple myeloma
measurable disease
Investigational Site Number 8400003
 (7.8 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +7 other locations
Test trial v7.2 (May 13) - Test 1 (Acro - Test 1)

Test trial v7.2 (May 13) - Test 1

US-Site 1
 (7.1 away) Contact site
  • 0 views
  • 09 Jul, 2026
  • +2 other locations
Identification of Predictors for Clinical Outcomes in Femoroacetabular Impingement Surgery

The overarching goal of the study is to improve the surgical treatment outcomes of FAI, which is affecting an increasing number of military personnel and young active individuals in the general population. The proposed study will investigate critical patient, disease, and surgical treatment predictors of FAI surgery outcomes.

hip arthroscopy
arthroscopy
conservative management
femoroacetabular impingement
Boston Children's Hospital
 (7.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +11 other locations
Genome Environment Microbiome and Metabolome in Autism Study

GEMMA is a multicenter longitudinal observational study that follows children who are genetically at-risk of developing autism for their first three years of life, seeking to identify potential biomarkers predictive of autism development in the blood, stool, urine and saliva. The biomarkers identified in this project will contribute to a …

autism
Massachusetts General Hospital for Children
 (8.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +2 other locations
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …

resting tremor
bradykinesia
modafinil
genetic testing
muscle rigidity
Boston University
 (7.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +45 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

gaucher disease
eliglustat
deficiency
imiglucerase
Investigational Site Number 840092
 (7.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +220 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840093
 (7.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +135 other locations